Vivax malaria

By R. Price, E. Tjitra, C. Guerra, S. Yeung, N. White, N. Anstey. American Journal of Tropical Medicine and Hygiene, 2007

839 citations recorded by the source corpus.

Plasmodium vivax threatens almost 40% of the world’s population, resulting in 132 - 391 million clinical infections each year. Most of these cases originate from South East Asia and the Western Pacific, although a significant number also occur in Africa and South America. Although often regarded as causing a benign and self-limiting infection, there is increasing evidence that the overall burden, economic impact and severity of disease from P. vivax have been underestimated. Malaria control strategies have had limited success and are confounded by the lack of access to reliable diagnosis, emergence of multidrug resistant isolates and the parasite’s ability to transmit early in the course of disease and relapse from dormant liver stages at varying time intervals after the initial infection. Progress in reducing the burden of disease will require improved access to reliable diagnosis and effective treatment of both blood-stage and latent parasites, and more detailed characterization of the epidemiology, morbidity and economic impact of vivax malaria. Without these, vivax malaria will continue to be neglected by ministries of health, policy makers, researchers and funding bodies.

Subfields: Parasitology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/4ccb08dfb584f87f1224fe1c667b0354938cf164

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Public Health, Environmental and Occupational Health

Citations in the corpus

Multidrug-Resistant Plasmodium vivax Associated with Severe and Fatal Malaria: A Prospective Study in Papua, Indonesia (2008, background): “vivax to other parts of Indonesia, Southeast Asia, and South America [3] highlights an urgent need to re-examine the spectrum and burden of vivax malaria and for appropriately resourced control measures to be implemented against this emerging but neglected disease.”
Effective Preparation of Plasmodium vivax Field Isolates for High-Throughput Whole Genome Sequencing (2013, positive): “Rising levels of multidrug resistance and severe disease have refocused efforts to better understand and control vivax malaria [2–8].”
A World Malaria Map: Plasmodium falciparum Endemicity in 2007 (2009, background): “vivax burden [103] despite its increasingly recognised clinical importance [104– 106], but have archived over 2,500 P.”
Determinants of relapse periodicity in Plasmodium vivax malaria (2011, background): “It is an important contributor to early pregnancy loss and reduced birth weight which increases mortality in infancy [1,2].”
Worldwide sequence conservation of transmission-blocking vaccine candidate Pvs230 in Plasmodium vivax (2011, background): “The elimination strategies are however limited and confounded by emergence of multidrug resistant isolates and relapse from dormant hypnozoites stages at varying time intervals after the initial infection and there have not been available any optimal chemotherapeutic agents to combat against these s”
Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction (2012, background): “Not only does this parasite transition between both extracellular and intracellular states during infection, but it can remain dormant in the liver and have greater transmission potential with lower titers than its more notorious counterpart, Plasmodium falciparum (1).”